Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CXA 10

Next Previous
Drug Profile

CXA 10

Alternative Names: 10-nitro-oleic-acid; CXA-10

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Complexa
  • Class Antihypertensives; Nitro compounds; Oleic acids; Small molecules; Unsaturated fatty acids; Urologics
  • Mechanism of Action Heat-shock protein stimulants; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Toll-like receptor 4 antagonists; Xanthine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis; Pulmonary arterial hypertension
  • No development reported Acute kidney injury; Renal failure

Most Recent Events

  • 31 Oct 2019 Complexa initiates enrolment in a phase II trial for Pulmonary arterial hypertension (In Adults, In the elderly) in USA (NCT04125745)
  • 17 Oct 2019 Complexa plans a phase IIa trial for Pulmonary arterial hypertension in USA in October 2019 (NCT04125745)
  • 04 Oct 2019 CXA 10 receives Orphan Drug status for Pulmonary arterial hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top